Anthem Biosciences Q4 Results 2026 Preview, Earnings Estimates & Outlook
Anthem Biosciences latest news:
Updated: 24 Mar 2026 • 1:15 pm
Posted by:
Anthem Biosciences Q4 Results 2026 Preview
- Anthem Biosciences Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 17-23% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 19-26% YoY.
- EBITDA to rise 18-24%.
- Anthem Biosciences is expected to show Strong Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Anthem Biosciences Share Performance
- Over the past six months, Anthem Biosciences share price has Up by 30% to 644.75.
- Moreover, over the past year, the stock has Up by 52%
- Despite this weak short-term performance, Anthem Biosciences stock has delivered a financially sound 260% return over the past 5 years.
- As of today, 20-03-2026, the Anthem Biosciences share price is trading at 644.75 per share.
Key Factors to Watch for Anthem Biosciences Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Biotechnology & CRAMS industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
Visit Univest app or website to check more Anthem Biosciences latest news to make an informed investment decision.
About Anthem Biosciences
Anthem Biosciences is a biotechnology and pharmaceutical research company offering contract research manufacturing and drug discovery services to global pharmaceutical firms.
Visit Univest app or website to check more Anthem Biosciences latest news to make an informed investment decision.
Final Thoughts
Anthem Biosciences is gear up to announce its Q4 FY26 results. Analysts expect 17-23% revenue growth, a 19-26% rise in PAT, and a 18-24% rise in EBITDA. Anthem Biosciences focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Anthem Biosciences Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
AMD Industries Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Ambika Cotton Mills Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Amagi Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Alphageo Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Almondz Global Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times